Orchestra BioMed Holdings, Inc./$OBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Ticker
$OBIO
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
70
ISIN
US68572M1062
Website
OBIO Metrics
BasicAdvanced
$114M
-
-$1.77
0.66
-
Price and volume
Market cap
$114M
Beta
0.66
52-week high
$5.04
52-week low
$2.37
Average daily volume
216K
Financial strength
Current ratio
3.351
Quick ratio
3.226
Long term debt to equity
94.05
Total debt to equity
97.55
Interest coverage (TTM)
-90.64%
Profitability
EBITDA (TTM)
-68.482
Gross margin (TTM)
92.58%
Net profit margin (TTM)
-2,297.85%
Operating margin (TTM)
-2,383.89%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-60.70%
Return on equity (TTM)
-179.12%
Valuation
Price to revenue (TTM)
38.655
Price to book
6.77
Price to tangible book (TTM)
6.77
Price to free cash flow (TTM)
-2.049
Free cash flow yield (TTM)
-48.81%
Free cash flow per share (TTM)
-145.46%
Growth
Revenue change (TTM)
30.23%
Earnings per share change (TTM)
20.64%
3-year revenue growth (CAGR)
32.81%
3-year earnings per share growth (CAGR)
-35.02%
OBIO News
AllArticlesVideos
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
GlobeNewsWire·1 week ago
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
GlobeNewsWire·2 months ago
Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Orchestra BioMed Holdings, Inc. stock?
Orchestra BioMed Holdings, Inc. (OBIO) has a market cap of $114M as of June 28, 2025.
What is the P/E ratio for Orchestra BioMed Holdings, Inc. stock?
The price to earnings (P/E) ratio for Orchestra BioMed Holdings, Inc. (OBIO) stock is 0 as of June 28, 2025.
Does Orchestra BioMed Holdings, Inc. stock pay dividends?
No, Orchestra BioMed Holdings, Inc. (OBIO) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Orchestra BioMed Holdings, Inc. dividend payment date?
Orchestra BioMed Holdings, Inc. (OBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Orchestra BioMed Holdings, Inc.?
Orchestra BioMed Holdings, Inc. (OBIO) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.